Fox Chase Cancer Center — CureCurrent

How to interpret these research links

Connected source records

The exact organization name Fox Chase Cancer Center appears in 78 distinct published trial records. The links retain registry-reported sponsor and collaborator roles; differently spelled legal entities are not automatically merged. Recruiting status describes the current published registry snapshot, not an independently verified availability guarantee.

Data basis: current published ClinicalTrials.gov records and, where present, RxNorm, MONDO and FDA-label identifiers. See the evidence interpretation and counting methodology.

Published trials78

Recruiting shown2

Roles2

SourceClinicalTrials.gov

Clinical trials

60 shown

Adaptive Radiation Therapy for Men With Intermediate- or High-Risk Prostate CancerNCT07219303 · lead sponsor · 2025-09-25

Dose Attenuated Chemotherapy in Compromised Patients With Lung CancerNCT05800587 · lead sponsor · 2023-02-22

Blood Testing to Detect Cancer Recurrence in Patients With Early-Stage Non-Small Cell Lung CancerNCT07854769 · lead sponsor · 2026-10-06

NOT_YET_RECRUITING

Iadademstat in Combination With Paclitaxel in Relapsed/Refractory SCLC and Extrapulmonary High Grade NETNCT05420636 · lead sponsor · 2022-12-21

African Cancer Genome: GMDNCT05754658 · lead sponsor · 2022-11-28

Sotorasib in KRAS G12C Mutated, Resectable, Stage Ib-IIIA NSCLCNCT05400577 · lead sponsor · 2022-07-13

Feasibility Study on Expandion of MILs From NSCLC and SCLC Patients and Infusion With PembrolizumabNCT04677361 · lead sponsor · 2021-10-01

Couples' QOL in Metastatic Breast CancerNCT05636943 · lead sponsor · 2021-01-01

ACTIVE_NOT_RECRUITING

Nivolumab Plus Ramucirumab in Patients With Recurrent, Advanced, Metastatic NSCLCNCT03527108 · lead sponsor · 2020-10-08

ACTIVE_NOT_RECRUITING

Clinician Communication About Sexual HealthNCT04262219 · lead sponsor · 2020-02-07

Phase II Randomized Trial of Carboplatin+Pemetrexed+Bevacizumab+/- Atezolizumab in Stage IV NSCLCNCT03786692 · lead sponsor · 2019-09-04

ACTIVE_NOT_RECRUITING

Coping Together After Breast CancerNCT03930797 · lead sponsor · 2019-05-24

Utility of CAML as Diagnostic for Early Stage Lung CancerNCT03992183 · lead sponsor · 2019-05-21

Addressing Sexual Concerns in Breast Cancer: Patient Intervention StudyNCT03624972 · lead sponsor · 2018-05-27

Pilot Study to Investigate The Diagnostic Yield and Utility of 22g and 19g Endobronchial Ultrasound Transbronchial Needle AspirateNCT03311620 · lead sponsor · 2018-05-15

Depletion of Myeloid Derived Suppressor Cells to Enhance Anti PD-1 TherapyNCT03302247 · lead sponsor · 2018-01-15

Clinical Trial of Atezolizumab With Paclitaxel, Trastuzumab, and Pertuzumab in Patients With Metastatic HER-2 Positive Breast CancerNCT03125928 · lead sponsor · 2017-06-13

ACTIVE_NOT_RECRUITING

Phase I/II Study of Lenalidomide Plus Pembrolizumab in Patients With Solid Tumors With Expansion in Non-small Cell Lung CancerNCT02963610 · lead sponsor · 2017-03-29

Pulsed Low Dose Rate Radiation With Concurrent Chemotherapy for Non-Small Cell Lung Cancer and Esophageal CancerNCT03094884 · lead sponsor · 2017-02-24

Observation Study of Patients With Non-Small Cell Lung Cancer and Esophageal Cancer Treated With Chemo-Radiation Followed by SurgeryNCT03095209 · lead sponsor · 2017-02-24

Improving the Approach to and Management of the Older Metastatic Breast Cancer PatientNCT03007641 · lead sponsor · 2016-11-01

A Study of Pembrolizumab With Carboplatin and Gemcitabine in Patients With Metastatic Triple Negative Breast CancerNCT02755272 · lead sponsor · 2016-05-31

ACTIVE_NOT_RECRUITING

A Biobehavioral Model of Diabetes Risk in Chinese ImmigrantsNCT02449213 · lead sponsor · 2016-03-11

Bicalutamide With or Without Metformin for Biochemical Recurrence in Overweight or Obese Prostate Cancer PatientsNCT02614859 · lead sponsor · 2015-12-01

Pilot Study of an Intimacy Enhancement Intervention for Couples Facing Breast CancerNCT02721147 · lead sponsor · 2015-10-27

Genetic Sequencing-Informed Targeted Therapy in Treating Patients With Stage IIIB-IV Non-small Cell Lung CancerNCT02132884 · lead sponsor · 2015-03-01

Technology and Health Communication in Improving Health Outcomes in Patients Scheduled for MammographyNCT04290585 · lead sponsor · 2014-03-05

Adherence to Survivorship Care Guidelines in Health Care Providers for Non-Small Cell Lung Cancer and Colorectal Cancer Survivor CareNCT01726296 · lead sponsor · 2013-01-01

Study to Evaluate NA-NOSE for Monitoring and Detecting Recurrence in Early Stage Lung CancerNCT01840150 · lead sponsor · 2012-08-23

Development of Real-time Image-guided RadiotherapyNCT03524248 · lead sponsor · 2012-05-17

Trial of an Online Multimedia Program to Boost Coping & Function for Prostate Cancer Survivors (PROGRESS)NCT02224482 · lead sponsor · 2012-02-01

Study to Assess Safety and Tolerability of MLN8237, In Combination With Erlotinib to Treat Non-Small Cell Lung CancerNCT01471964 · lead sponsor · 2011-10-20

Heavy Metal Exposure in Predicting Peripheral Neuropathy in Patients With Stage I-III Breast Cancer Undergoing ChemotherapyNCT01982591 · lead sponsor · 2011-01-03

Trial of Print Messages to Support the Role of Partners in Promoting Provider Discussions About Prostate Cancer Screening Among AA MenNCT01937585 · lead sponsor · 2010-08-01

Treatment of Locally Advanced Non-Small Cell Lung Cancer (NSCLC)NCT01059552 · lead sponsor · 2009-12-16

Recombinant Human Chorionic Gonadotropin in Preventing Breast Cancer in Premenopausal Women With BRCA1 MutationsNCT00700778 · lead sponsor · 2008-07-01

Sorafenib in Hormone Naïve Biochemical Recurrence of Prostate CancerNCT00694291 · lead sponsor · 2008-06-01

Couple-Focused Intervention for Breast Cancer PatientsNCT00940277 · lead sponsor · 2007-12-01

Study of Bevacizumab and Erlotinib in Patients With Advanced Non-small Cell Lung CancerNCT00553800 · lead sponsor · 2007-07-05

Physical Activity or Usual Care in Preventing Weight Gain in Women With Stage I or Stage II Breast Cancer Undergoing ChemotherapyNCT00509626 · lead sponsor · 2007-06-01

Long-Term Effect of Adolescent Diet on Hormones and Breast Cancer Risk in Women Previously Enrolled in the Dietary Intervention Study in ChildrenNCT00458588 · lead sponsor · 2006-09-01

Printed Education Materials in Patients Who Are Finishing Treatment for Stage I, Stage II, or Stage IIIA Breast Cancer, Colorectal Cancer, Prostate Cancer, or Chest CancerNCT00372840 · lead sponsor · 2006-05-01

Counseling and Nicotine Replacement Therapy in Helping Adult Smokers Quit SmokingNCT00365508 · lead sponsor · 2006-02-01

Evaluation of the Efficacy of National Cancer Institute's Facing Forward Booklet in the Cancer Community SettingNCT01440855 · lead sponsor · 2005-02-01

Study of Paclitaxel, Carboplatin, and Cetuximab for Advanced Lung CancerNCT00315185 · lead sponsor · 2004-12-01

Intensity-Modulated Radiation Therapy With or Without Decreased Radiation Dose to Erectile Tissue in Treating Patients With Stage II Prostate CancerNCT00084552 · lead sponsor · 2003-12-11

Paclitaxel, Topotecan, and Estramustine in Treating Patients With Metastatic Hormone-Refractory Prostate CancerNCT00084565 · lead sponsor · 2003-11-01

Computed Tomography (CT) Scans Using CT-On-Rails™ to Pinpoint the Location of the Tumor in Treating Patients With Prostate CancerNCT00084526 · lead sponsor · 2003-11-01

Adjuvant Hypofractionated Intensity-Modulated Radiation Therapy With Incorporated Boost in Treating Patients With Early-Stage Breast CancerNCT00084539 · lead sponsor · 2003-11-01

Neoadjuvant Chemoradiotherapy Followed By Surgery in Treating Patients With Limited-Stage Small Cell Lung CancerNCT00062322 · lead sponsor · 2003-02-01

Combination Chemotherapy, Surgery, and Radiation Therapy in Treating Patients With Non-Small Cell Lung CancerNCT00043108 · lead sponsor · 2002-07-01

Radiofrequency Ablation During Surgery in Treating Patients With Non-Small Cell Lung CancerNCT00039507 · lead sponsor · 2002-06-01

Comparison of Two Radiation Therapy Regimens in Treating Patients With Stage II or Stage III Prostate CancerNCT00062309 · lead sponsor · 2002-06-01

Temozolomide in Treating Patients With Relapsed or Progressive Small Cell Lung CancerNCT00022711 · lead sponsor · 2002-01-01

Sulindac and Docetaxel in Treating Women With Metastatic or Recurrent Breast CancerNCT00039520 · lead sponsor · 2002-01-01

Combination Chemotherapy in Treating Patients With Stage IIIB, Stage IV, or Recurrent Non-Small Cell Lung CancerNCT00054392 · lead sponsor · 2001-09-01

R115777 in Treating Patients With Progressive, Metastatic Prostate Cancer That Has Not Responded to Hormone TherapyNCT00005848 · lead sponsor · 2000-04-01

Temozolomide in Treating Patients With Stage IIIB, Stage IV, or Recurrent Non-small Cell Lung CancerNCT00005037 · lead sponsor · 2000-01-01

Paclitaxel and Cisplatin Plus Radiation Therapy Followed by Filgrastim in Treating Patients With Recurrent Head and Neck Cancer or Lung CancerNCT00021333 · lead sponsor · 1999-09-01

Chemotherapy and Radiation Therapy in Treating Patients With Non-Small Cell Lung CancerNCT00022308 · lead sponsor · 1999-01-01

Drugs studied in this sponsor's trials

29 mapped RxNorm concepts

These drug records are connected through ClinicalTrials.gov studies listing Fox Chase Cancer Center as a sponsor, collaborator or responsible party. Each count is the number of distinct trials containing the mapped drug intervention. This does not establish that the organization manufactures, owns, sells or developed the drug.

Most studied mapped drug conceptsDistinct linked trials per RxNorm concept; one trial may study several drugs.

paclitaxel10

carboplatin8

cisplatin4

cyclophosphamide2

docetaxel2

etoposide2

gemcitabine2

irinotecan hydrochloride2

paclitaxel RxCUI 56946 · Lead sponsor in 10 linked trial(s) · 1 currently recruiting 10 trials carboplatin RxCUI 40048 · Lead sponsor in 7 linked trial(s) · 1 currently recruiting 8 trials cisplatin RxCUI 2555 · Lead sponsor in 4 linked trial(s) · 0 currently recruiting 4 trials cyclophosphamide RxCUI 3002 · Lead sponsor in 1 linked trial(s) · 0 currently recruiting 2 trials docetaxel RxCUI 72962 · Lead sponsor in 2 linked trial(s) · 1 currently recruiting 2 trials etoposide RxCUI 4179 · Lead sponsor in 1 linked trial(s) · 1 currently recruiting 2 trials gemcitabine RxCUI 12574 · Lead sponsor in 2 linked trial(s) · 1 currently recruiting 2 trials irinotecan hydrochloride RxCUI 153329 · Lead sponsor in 2 linked trial(s) · 0 currently recruiting 2 trials pembrolizumab RxCUI 1547545 · Lead sponsor in 2 linked trial(s) · 0 currently recruiting 2 trials temozolomide RxCUI 37776 · Lead sponsor in 2 linked trial(s) · 0 currently recruiting 2 trials topotecan hydrochloride RxCUI 266573 · Lead sponsor in 2 linked trial(s) · 0 currently recruiting 2 trials atezolizumab RxCUI 1792776 · Lead sponsor in 1 linked trial(s) · 0 currently recruiting 1 trial bevacizumab RxCUI 253337 · Lead sponsor in 1 linked trial(s) · 0 currently recruiting 1 trial cetuximab RxCUI 318341 · Lead sponsor in 1 linked trial(s) · 0 currently recruiting 1 trial erlotinib RxCUI 337525 · Lead sponsor in 1 linked trial(s) · 0 currently recruiting 1 trial gemcitabine hydrochloride RxCUI 236234 · Lead sponsor in 1 linked trial(s) · 0 currently recruiting 1 trial irinotecan RxCUI 51499 · Lead sponsor in 1 linked trial(s) · 1 currently recruiting 1 trial lenalidomide RxCUI 342369 · Lead sponsor in 1 linked trial(s) · 0 currently recruiting 1 trial lurbinectedin RxCUI 2374729 · Lead sponsor in 1 linked trial(s) · 1 currently recruiting 1 trial mesna RxCUI 44 · Lead sponsor in 0 linked trial(s) · 0 currently recruiting 1 trial nivolumab RxCUI 1597876 · Lead sponsor in 1 linked trial(s) · 0 currently recruiting 1 trial pemetrexed RxCUI 68446 · Lead sponsor in 1 linked trial(s) · 1 currently recruiting 1 trial pertuzumab RxCUI 1298944 · Lead sponsor in 1 linked trial(s) · 0 currently recruiting 1 trial ramucirumab RxCUI 1535922 · Lead sponsor in 1 linked trial(s) · 0 currently recruiting 1 trial

Sponsor roles

lead sponsor64

collaborator14

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.